Summary:

- The article presents the findings of a study that investigated the potential of a novel vaccine candidate, named SARS-CoV-2 RBD-Fc, for providing protection against COVID-19.
- The researchers developed the SARS-CoV-2 RBD-Fc vaccine, which is designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, and tested its efficacy in animal models.
- The results showed that the SARS-CoV-2 RBD-Fc vaccine was able to elicit a strong and durable immune response, providing protection against SARS-CoV-2 infection and reducing disease severity in the animal models.